- Home
- VKI vs MYGN Comparison
VKI vs MYGN Comparison
Compare VKI & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VKI
- MYGN
- Stock Information
- Founded
- VKI 1993
- MYGN 1991
- Country
- VKI United States
- MYGN United States
- Employees
- VKI N/A
- MYGN N/A
- Industry
- VKI Finance Companies
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- VKI Finance
- MYGN Health Care
- Exchange
- VKI Nasdaq
- MYGN Nasdaq
- Market Cap
- VKI 377.0M
- MYGN 423.1M
- IPO Year
- VKI N/A
- MYGN 1995
- Fundamental
- Price
- VKI $8.30
- MYGN $6.02
- Analyst Decision
- VKI
- MYGN Hold
- Analyst Count
- VKI 0
- MYGN 13
- Target Price
- VKI N/A
- MYGN $13.50
- AVG Volume (30 Days)
- VKI 112.8K
- MYGN 2.4M
- Earning Date
- VKI 01-01-0001
- MYGN 08-05-2025
- Dividend Yield
- VKI 4.52%
- MYGN N/A
- EPS Growth
- VKI N/A
- MYGN N/A
- EPS
- VKI N/A
- MYGN N/A
- Revenue
- VKI N/A
- MYGN $832,900,000.00
- Revenue This Year
- VKI N/A
- MYGN N/A
- Revenue Next Year
- VKI N/A
- MYGN $6.64
- P/E Ratio
- VKI N/A
- MYGN N/A
- Revenue Growth
- VKI N/A
- MYGN 3.83
- 52 Week Low
- VKI $7.07
- MYGN $3.76
- 52 Week High
- VKI $8.98
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- VKI 50.41
- MYGN 62.34
- Support Level
- VKI $8.25
- MYGN $5.23
- Resistance Level
- VKI $8.45
- MYGN $6.07
- Average True Range (ATR)
- VKI 0.06
- MYGN 0.39
- MACD
- VKI -0.01
- MYGN 0.05
- Stochastic Oscillator
- VKI 24.00
- MYGN 81.27
About VKI Invesco Advantage Municipal Income Trust II of Beneficial Interest (DE)
Invesco Advantage Municipal Income Trust II is a diversified, closed-end management investment company. The investment objective of the company is to provide common shareholders with a high level of current income exempt from federal income tax, consistent with preservation of capital.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.